WVE 10-K/A

WVE 10-K/A

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Wave Life Sciences, Inc. (WVE)

10-K/A 2023-05-05 For: 2022-12-31

View Original

Added on April 09, 2026

Search and read filings like this one from Claude or ChatGPT with the SEC filings MCP server →


Singapore		98-1356880
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

7 Straits View #12-00 , Marina One East Tower Singapore		018936
(Address of principal executive offices)		(Zip code)


Title of each class	Trading symbol	Name of each exchange on which registered
$0 Par Value Ordinary Shares	WVE	The Nasdaq Global Market


PART III		1
Item 10.	Directors, Executive Officers and Corporate Governance	1
Item 11.	Executive Compensation	8
Item 12.	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	16
Item 13.	Certain Relationships and Related Transactions, and Director Independence	19
Item 14.	Principal Accountant Fees and Services	21
PART IV		22
Item 15.	Exhibits and Financial Statement Schedules	22
Item 16.	Form 10-K Summary	26
Signatures		27


Name	Age	Position/Title
Paul B. Bolno, M.D., MBA	49	President, Chief Executive Officer and Director
Christian Henry	55	Chairman of the Board
Mark H. N. Corrigan, M.D.	65	Director
Peter Kolchinsky, Ph.D.	46	Director
Adrian Rawcliffe	50	Director
Ken Takanashi	58	Director
Aik Na Tan	52	Director
Gregory L. Verdine, Ph.D.	63	Director
Heidi L. Wagner, J.D.	58	Director

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Emerging growth company


Board Diversity Matrix (As of March 24, 2023)
Total Number of Directors
9
	Female		Male
Gender:
Directors		2		7
Number of Directors Who Identify in Any of the Categories Below:
Asian		1		1
White		1		6


Name	Age	Title
Christopher Francis, Ph.D.	45	Senior Vice President, Corporate Development, Head of Emerging Areas
Kyle Moran, CFA	52	Chief Financial Officer
Chandra Vargeese, Ph.D.	61	Chief Technology Officer, Head of Platform Discovery Sciences


Name and Principal Position	Year		Salary ($)		Share Awards ($)⁽¹⁾		Option Awards ($)⁽²⁾		Non-Equity Incentive Plan Compensation ($)		All Other Compensation ($)⁽³⁾		Total ($)
Paul B. Bolno, M.D., MBA		2022		617,900		—		1,565,220		461,900		22,977		2,667,997
President and Chief Executive Officer		2021		597,000		1,572,000		1,326,000		388,100		9,510		3,892,610
Chandra Vargeese, Ph.D.		2022		459,540		—		521,740		237,800		12,714		1,231,794
Chief Technology Officer, Head of Platform Discovery Sciences		2021		444,000		524,000		331,500		199,800		12,264		1,511,564
Kyle Moran, CFA		2022		439,875		—		470,923		227,600		10,392		1,148,790
Chief Financial Officer


	Option Awards									Share Awards
Name	Number of Securities Underlying Unexercised Options (#) Exercisable		Number of Securities Underlying Unexercised Options (#) Unexercisable			Option Exercise Price ($)		Option Expiration Date		Number of Shares or Share Units That Have Not Vested (#)			Market Value of Shares or Share Units That Have Not Vested ($)⁽⁷⁾		Equity Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights That Have Not Vested (#)			Equity Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Vested ($)⁽⁷⁾
Paul B. Bolno, M.D., MBA		219,025		—		$	2.48		3/10/2025
		236,400		—		$	18.79		6/16/2026
		72,500		—		$	29.05		1/25/2027
		109,000				$	40.05		1/23/2028
		63,000				$	8.17		3/3/2030
		100,000		100,000	⁽¹⁾	$	10.48		2/1/2031
		—		600,000	⁽²⁾	$	3.14		1/1/2032
		—		180,000	⁽³⁾	$	2.83		7/25/2032
											15,000	⁽⁴⁾	$	105,000
											75,000	⁽⁵⁾	$	525,000
																92,500	⁽⁶⁾	$	647,500


Name	Fees Earned or Paid in Cash ($)⁽¹⁾		Option Awards ($)⁽²⁾		All Other Compensation ($)			Total ($)
Christian Henry		99,000		45,152		—			144,152
Mark H. N. Corrigan, M.D.		71,500		45,152		—			116,652
Peter Kolchinsky, Ph.D.(3)		47,500		45,152		—			92,652
Adrian Rawcliffe		65,500		45,152		—			110,652
Ken Takanashi		47,500		45,152		—			92,652
Aik Na Tan		49,000		45,152		—			94,152
Gregory L. Verdine, Ph.D.		47,500		468,058		112,500	⁽⁴⁾		628,058
Heidi L. Wagner, J.D.		62,500		45,152		—			107,652


	Aggregate
	Number of
	Shares
	Subject to
Name	Options
Christian Henry		93,000
Mark H. N. Corrigan, M.D.		73,500
Peter Kolchinsky, Ph.D.		93,000
Adrian Rawcliffe		93,000
Ken Takanashi		93,000
Aik Na Tan		63,000
Gregory L. Verdine, Ph.D.(1)		522,869
Heidi L. Wagner, J.D.		73,500


	Ordinary Shares Beneficially Owned
Name	Shares		Percent
5% Beneficial Owners
RA Capital Management, L.P.⁽¹⁾		20,225,708		19.99	%
GSK plc⁽²⁾		10,683,761		10.9	%
Shin Nippon Biomedical Laboratories, Ltd.⁽³⁾		9,606,408		9.4	%
Maverick Capital, Ltd.⁽⁴⁾		7,097,664		7.2	%
683 Capital Management, LLC⁽⁵⁾		6,000,000		6.1	%
M28 Capital Management LP⁽⁶⁾		5,903,405		6.0	%
Adage Capital Partners, L.P.⁽⁷⁾		5,526,884		5.6	%
Directors and Named Executive Officers
Paul B. Bolno, M.D., MBA⁽⁸⁾		1,494,850		1.5	%
Chandra Vargeese, Ph.D.⁽⁹⁾		554,910			*
Kyle Moran, CFA⁽¹⁰⁾		261,242			*
Mark H. N. Corrigan, M.D.⁽¹¹⁾		49,875			*
Christian Henry⁽¹¹⁾		66,750			*
Peter Kolchinsky, Ph.D.⁽¹²⁾		20,225,708		19.99	%
Adrian Rawcliffe⁽¹¹⁾		66,750			*
Ken Takanashi⁽¹³⁾		9,673,158		9.5	%
Heidi L. Wagner, J.D.⁽¹¹⁾		49,875			*
Gregory L. Verdine, Ph.D.⁽¹⁴⁾		405,532			*
Aik Na Tan⁽¹¹⁾		34,730			*
All current directors and executive officers as a group (12 individuals)⁽¹⁵⁾		33,219,566		30.8	%


Plan Category	Number of Securities to be Issued upon Exercise of Outstanding Options, Warrants and Rights			Weighted-Average Exercise Price of Outstanding Options, Warrants and Rights			Number of Securities Remaining Available for Future Issuance under Equity Compensation Plans
Equity compensation plans approved by security holders		10,549,896	⁽¹⁾	$	7.73	⁽²⁾		7,055,893	⁽³⁾
Equity compensation plans not approved by security holders		66,500	⁽⁴⁾	$	8.95	⁽⁵⁾		—
Total		10,616,396		$	7.73			7,055,893


	2022		2021
Audit fees (1)	$	1,209,625	$	$977,558
Audit-related fees (2)		—		—
Tax fees (2)		—		—
All other fees (2)		—		—


Exhibit Number	Exhibit Description	Filed with this Report	Incorporated by Reference herein from Form or Schedule	Filing Date	SEC File/Reg. Number

3.1	Constitution (formerly known as Memorandum of Association and Articles of Association)		Amendment No. 5 to Form S-1 (Exhibit 3.2)	11/10/2015	333-207379

4.1	Form of Specimen Ordinary Share Certificate		Amendment No. 3 to Form S-1 (Exhibit 4.1)	11/06/2015	333-207379

4.2	Description of Securities of the Registrant and Comparison of Shareholder Rights		Form 10-K (Exhibit 4.2)	03/23/2023	001-37627

4.3	Form of Pre-Funded Warrant		Form 8-K (Exhibit 4.1)	06/14/2022	001-37627

4.4.1	Investors’ Rights Agreement by and among the Registrant and certain of its shareholders, dated as of August 14, 2015		Form S-1 (Exhibit 4.2)	10/09/2015	333-207379

4.4.2	Amendment No. 1 to Investors’ Rights Agreement by and among the Registrant and certain of its shareholders, dated as of November 8, 2018		Form 10-Q (Exhibit 10.2)	11/09/2018	001-37627


Exhibit Number	Exhibit Description	Filed with this Report	Incorporated by Reference herein from Form or Schedule	Filing Date	SEC File/Reg. Number

10.23.3+	Form of Restricted Share Unit Agreement under the 2014 Equity Incentive Plan, effective as of January 1, 2019		Form 10-Q (Exhibit 10.1)	05/10/2019	001-37627

10.23.4+	Form of Restricted Share Unit Agreement under the 2021 Equity Plan, effective as of August 10, 2021		Form 10-Q (Exhibit 10.4)	11/10/2021	001-37627

10.23.5+	Form of Amended and Restated 2019 Performance-Based Restricted Share Unit Agreement under the 2014 Equity Incentive Plan, effective as of March 17, 2021		Form 10-Q (Exhibit 10.2)	05/13/2021	001-37627

10.23.6+	Form of 2021 Performance-Based Restricted Share Unit Agreement under the 2014 Equity Incentive Plan, effective as of March 17, 2021		Form 10-Q (Exhibit 10.3)	05/13/2021	001-37627

10.24.1+	Form of Non-qualified Share Option Agreement for UK Participants under the 2014 Equity Plan, effective as of June 21, 2017		Form 10-Q (Exhibit 10.5)	11/09/2017	001-37627

10.24.2+	Form of Non-qualified Share Option Agreement for UK Participants under the 2014 Equity Plan, effective as of January 1, 2018		Form 10-K (Exhibit 10.26.2)	03/01/2019	001-37627

10.24.3+	Form of Non-qualified Share Option Agreement for UK Participants under the 2021 Equity Plan, effective as of August 10, 2021		Form 10-Q (Exhibit 10.5)	11/10/2021	001-37627

10.24.4+	Form of Restricted Share Unit Agreement for UK Participants under the 2021 Equity Plan, effective as of August 10, 2021		Form 10-Q (Exhibit 10.6)	11/10/2021	001-37627

10.25.1	Form of Inducement Non-qualified Share Option Agreement		Form 10-Q (Exhibit 10.3)	08/10/2020	001-37627

10.25.2	Form of Inducement Restricted Share Unit Agreement		Form 10-Q (Exhibit 10.7)	11/10/2021	001-37627

10.26.1	Open Market Sale Agreement, dated as of May 10, 2019, by and between the Registrant and Jefferies LLC		Form S-3ASR (Exhibit 1.2)	05/10/2019	333-231382

10.26.2	Amendment No. 1 to Open Market Sale Agreement, dated as of March 2, 2020, by and between the Registrant and Jefferies LLC		POSASR (Exhibit 1.3)	03/02/2020	333-231382

10.26.3	Amendment No. 2, dated March 3, 2022, to the Open Market Sale Agreement, dated as of May 10, 2019, by and between Wave Life Sciences Ltd. and Jefferies LLC		Form 8-K (Exhibit 10.1)	03/03/2022	001-37627

21.1	List of Subsidiaries of the Registrant		Form 10-K (Exhibit 21.1)	03/12/2018	001-37627

23.1	Consent of Independent Registered Public Accounting Firm		Form 10-K (Exhibit 23.1)	03/23/2023	001-37627

24.1	Power of Attorney (included on signature page to the Original 10-K)		Form 10-K (Exhibit 24.1)	03/23/2023	001-37627

31.1	Certifications of Principal Executive Officer pursuant to Rule 13a-14(a)	X

31.2	Certifications of Principal Financial Officer pursuant to Rule 13a-14(a)	X

32*	Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, by Principal Executive Officer and Principal Financial Officer.		Form 10-K (Exhibit 32)	03/23/2023	001-37627